Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases
Taebum Lee, Boram Lee, Yoon-La Choi, Joungho Han, Myung-Ju Ahn, Sang-Won Um
J Pathol Transl Med. 2016;50(3):197-203.   Published online 2016 Apr 18     DOI: https://doi.org/10.4132/jptm.2016.03.09
Citations to this article as recorded by Crossref logo
Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity
Alexios Matikas, Dimitrios Mistriotis, Vasilios Georgoulias, Athanasios Kotsakis
Critical Reviews in Oncology/Hematology.2017; 110: 1.     CrossRef
Clinical Outcome of ALK -Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)
Sabine Schmid, Oliver Gautschi, Sacha Rothschild, Michael Mark, Patrizia Froesch, Dirk Klingbiel, Hermann Reichegger, Wolfram Jochum, Joachim Diebold, Martin Früh
Journal of Thoracic Oncology.2017; 12(4): 681.     CrossRef
Concomitant Presence of EGFR and ALK Fusion Gene Mutation in Adenocarcinoma of Lung: A Case Report and Review of the Literature
Nishitha Thumallapally, Hana Yu, Mohammad Farhan, Uroosa Ibrahim, Maricel Odiami
Journal of Pharmacy Practice.2017; : 089719001770475.     CrossRef
Management of non-small cell lung cancer in the era of personalized medicine
Gaetano Rocco, Alessandro Morabito, Alessandra Leone, Paolo Muto, Francesco Fiore, Alfredo Budillon
The International Journal of Biochemistry & Cell B.2016; 78: 173.     CrossRef
A long-term survivor of non-small-cell lung cancer harboring concomitant EGFR mutation and ALK translocation
Fumio Imamura, Takako Inoue, Madoka Kimura, Kazumi Nishino, Toru Kumagai
Respiratory Medicine Case Reports.2016; 19: 137.     CrossRef